Pharmaceuticals News and Research

RSS

EPA continues to validate ToxCast screening tool by testing more than 100 drugs

The U.S. Environmental Protection Agency will continue validating its ToxCast screening tool by screening more than 100 drugs provided by Pfizer, GlaxoSmithKline, Sanofi-Aventis, and Merck. These drugs never entered the marketplace because they demonstrated different types and levels of toxicity when the pharmaceutical companies conducted the early stage clinical trials required by the Food and Drug Administration as part of the drug development process.

14 May 2010

Prometheus announces novel method for early detection of HACA during infliximab treatment

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced a new method for detecting antibody levels in individual patients treated with infliximab, a biologic therapy that has been used to treat more than a million patients across a number of autoimmune diseases, including rheumatoid arthritis, Crohn's disease and ulcerative colitis.

14 May 2010

India, Brazil launch trade dispute against EU, Netherlands over seizures of generic drugs

"India and Brazil launched a trade dispute against the European Union and the Netherlands on Wednesday, saying their seizures of generic drugs were hurting healthcare in poor countries and disrupting international trade," Reuters reports.

14 May 2010

Novel vaccines for deadly diseases to be presented at AAPS' NBC

Novel vaccines for diseases ranging from the flu to HIV highlight a week's worth of biotechnology research at the American Association of Pharmaceutical Scientists' National Biotechnology Conference. Scientists from academia, industry, and government will gather at the Hilton San Francisco Union Square Sunday, May 16 -Thursday, May 20 to share research and advances in biotherapeutics.

14 May 2010

Johns Hopkins Children's Center neonatologist joins NQF HIT advisory committee

Johns Hopkins Children's Center neonatologist Christoph Lehmann, M.D., has joined the nation's leading watchdog organization on health-care quality, the National Quality Forum (NQF), as a member of its newly formed Health Information Technology (HIT) advisory committee.

14 May 2010

BIO-key International first-quarter total revenue up 81%

BIO-key International, Inc., a leader in finger-based biometric identification solutions, today reported financial results for the first quarter ended March 31, 2010. For clarity and consistency, the data presented in this release includes only the results of the Company's fingerprint-based Biometrics Division for such period. The Company completed the sale of its Law Enforcement Division on December 8, 2009.

14 May 2010

caprotec bioanalytics closes EUR 4 million Series B Financing Round

caprotec bioanalytics GmbH today announced the closing of a EUR 4 million ($5.1M) Series B Financing Round with existing investors Creathor Venture, IBB Beteiligungsgesellschaft, ERP Startfonds, and well-known private investors. The proceeds will enable further development and marketing of the Company's proprietary CCMS (Capture Compound Mass Spectrometry) platform technology for analyzing complex protein mixtures.

14 May 2010

Phase IIb trail results of epratuzumab in lupus patients to be presented at EULAR 2010

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that clinical trial results on epratuzumab, the anti-CD22 humanized monoclonal antibody licensed to UCB SA, Brussels, for autoimmune disease indications, from the Phase IIb study in patients with lupus, will be presented in four posters sessions and one published abstract.

14 May 2010

Transdel Pharmaceuticals reports lower net loss of $0.9 million for first-quarter 2010

Transdel Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform, today announced financial results for the quarter ended March 31, 2010. The Company also highlighted recent achievements.

14 May 2010

Response Genetics first-quarter total revenue up 140%

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated financial results for the three months ended March 31, 2010.

14 May 2010

Celsis IVT settles LiverPool patent infringement suit, XenoTech to stop sale of CryoXTreme products

Celsis International Ltd. announced today that Celsis In Vitro, Inc. has reached a settlement agreement with XenoTech, LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. in a patent infringement lawsuit filed by Celsis IVT on February 2, 2010.

14 May 2010

Federal officials say crackdown on Medicare fraud recovers $2.5 billion

The Associated Press: "The government says it recovered $2.5 billion in overpayments for the Medicare trust fund last year as the Obama administration focused attention on fraud enforcement efforts in the health care industry. Investigators have new tools this year to help crack down on health care fraud, with the Justice Department and the Health and Human Services Department working cooperatively to police companies.

14 May 2010

Cyclacel Pharmaceuticals reports net loss of $5.1M for first-quarter 2010

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the first quarter ended March 31, 2010.

14 May 2010

Derma Sciences first-quarter net sales up 23% to $12,844,382

Derma Sciences, Inc., a specialty medical device/pharmaceutical company focused on advanced wound care, reported financial and operating results today for the three months ended March 31, 2010.

14 May 2010

Rexahn Pharmaceuticals announces Phase IIb clinical trial of Zoraxel for ED

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will initiate a Phase IIb clinical trial for ZoraxelTM in the treatment of erectile dysfunction (ED).

13 May 2010

ARCA biopharma regains compliance for continued listing on NASDAQ

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular disease, today announced that it received notification from the NASDAQ Stock Market that the Company has demonstrated compliance with the minimum stockholders' equity requirement for the NASDAQ Global Market

13 May 2010

Palatin Technologies reports net loss of $2.0M for third-quarter 2010

Palatin Technologies, Inc., a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics, today announced results for its third quarter ended March 31, 2010.

13 May 2010

Aradigm reports total revenue of $4.0M for first-quarter 2010

Aradigm Corporation today announced financial results for the first quarter and three months ended March 31, 2010.

13 May 2010

Arrowhead decreases second-quarter consolidated operating expenses by 58%

Arrowhead Research Corporation today announced financial results for its fiscal 2010 second quarter ended March 31, 2010.

13 May 2010

Genetic Immunity formulates first topically administered nanomedicine therapeutic vaccine for HIV/AIDS

Genetic Immunity, a multi-national biopharmaceutical company developing nanomedicine vaccines today announces publication of the Company's innovative work to develop a stable liquid formulation to deliver a novel nanomedicine. Appearing in the International Journal of Pharmaceutics, the paper addresses how Genetic Immunity was able to overcome significant hurdles facing the field to successfully formulate the first topically administered nanomedicine therapeutic vaccine for the treatment of HIV/AIDS, DermaVir.

13 May 2010